Before patients with cancer begin treatment with intravenous fluorouracil and related drugs, they should be tested for lack of the enzyme dihydropyrimidine dehydrogenase (DPD), says an EU panel.
Complete DPD deficiency markedly impairs 5-FU catabolism, increasing risk of early severe diarrhea, mucositis, neutropenia, ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Reply to: “Give Patients the Choice to Test for DPD Deficiency Before Fluoropyrimidine Chemotherapy,” “Large-Scale DPD Testing Should Be More Than an Option,” and “A Big Problem With a Feasible ...
Patients with cancer who are to receive fluorouracil (multiple brands) given by injection or infusion should be tested for lack of an enzyme called dihydropyrimidine dehydrogenase (DPD) prior to the ...
MedPage Today on MSN
FDA calls for testing before treatment with widely used chemotherapies
Notice highlights risks of DPD deficiency with capecitabine, fluorouracil ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results